m00osfoto / Shutterstock.com
A five-year period of data exclusivity available for biological drugs, as proposed in the Trans-Pacific Partnership (TPP) is long enough to encourage investment in the field, readers have said.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
patent, biologics, data exclusivity, Trans-Pacific Partnership, TPP,